A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 27 May 2010
At a glance
- Drugs Bendamustine; Rituximab
- Indications B cell lymphoma
- Focus Adverse reactions
- 27 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2010 Positive efficacy and tolerability results have been reported in a SymBio Pharmaceutical media release.
- 30 Nov 2008 Status changed from not yet recruiting to recruiting, as reported on ClinicalTrials.gov.